In this piece, Lindsay Lustig et al. discuss what they've learned from their multidisciplinary collaborations, and practical tips important in building strong team dynamics and ensuring the efficiency and productivity of your multidisciplinary research project.
'Receptor clustering control and associated force sensing by surface patterning: when force matters'
This Editorial article is featured in the new Special Focus Issue 'Engineering the nanoenvironment for regenerative medicine' published by Nanomedicine (IF: 5.824)
Achieving Gender Equality in Science, Engineering and Medicine - Seven Actionable Strategies for Advancing Women
Gender equality has not yet been achieved in science, medicine, and engineering, but NYSCF, through its Initiative on Women in Science and Engineering, is committed to making sure progress is made.
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it. In this interview with The Life Sciences Report, Vertès talks about some of the stem cell names he knows well, and draws comparisons investors can bank on.
As population gets older, local biotech companies aim to satisfy demand for youth-bestowing products. "Cell therapy is like personalized medicine. You don't have to pump yourself full of synthetics anymore. This uses your own cells," comments Lee Buckler, VP Business & Corp. Development, RepliCel Life Sciences.
Ahead of print foreword from Nanomedicine (Volume 10 Issue 05), a special focus on regenerative medicine, scheduled to be published in March
RepliCel's autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged and UV-damaged skin.
Newly Released Peer-Reviewed Publication Further Validates RepliCel’s Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.